Literature DB >> 16132763

Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.

Yuzo Furuya1, Remon Nishio, Akira Junicho, Osamu Nagakawa, Hideki Fuse.   

Abstract

To clarify whether serum levels of interleukin-11 (IL-11) could be a useful marker in patients with prostate cancer, serum IL-11 was determined in 73 and 23 men with prostate cancer and benign prostate hyperplasia (BPH), respectively, before treatment. There were no statistical differences of IL-11 levels between patients with prostate cancer and BPH. Patients with hormone-resistant prostate cancer had a significantly higher level of IL-11 than those with untreated cancer. Serum IL-11 levels may be a potential tumor marker for prostate cancer progression.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16132763     DOI： 10.1007/s11255-004-6086-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  12 in total

Review 1.  Interleukin-11: review of molecular, cell biology, and clinical use.

Authors:  X Du; D A Williams
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

Review 2.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

3.  Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases.

Authors:  C Sotiriou; M Lacroix; L Lespagnard; D Larsimont; M Paesmans; J J Body
Journal:  Cancer Lett       Date:  2001-08-10       Impact factor: 8.679

4.  Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation.

Authors:  B Knoefel; K Nuske; T Steiner; K Junker; H Kosmehl; K Rebstock; D Reinhold; U Junker
Journal:  J Interferon Cytokine Res       Date:  1997-02       Impact factor: 2.607

5.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma.

Authors:  C L Campbell; Z Jiang; D M Savarese; T M Savarese
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer.

Authors:  J Nakashima; M Tachibana; Y Horiguchi; M Oya; T Ohigashi; H Asakura; M Murai
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

7.  Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.

Authors:  S Akimoto; A Okumura; H Fuse
Journal:  Endocr J       Date:  1998-04       Impact factor: 2.349

8.  Interleukin-11: a new cytokine critical for osteoclast development.

Authors:  G Girasole; G Passeri; R L Jilka; S C Manolagas
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

9.  Production and regulation of interleukin-11 by breast cancer cells.

Authors:  M Lacroix; B Siwek; P J Marie; J J Body
Journal:  Cancer Lett       Date:  1998-05-15       Impact factor: 8.679

10.  Interleukin-11 inhibits bone formation in vitro.

Authors:  F J Hughes; G L Howells
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333
View more
  4 in total

1.  Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1.

Authors:  Xuhui Zhang; Hai Wu; Jason R Dobson; Gillian Browne; Deli Hong; Jacqueline Akech; Lucia R Languino; Gary S Stein; Jane B Lian
Journal:  J Cell Biochem       Date:  2015-09       Impact factor: 4.429

2.  Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.

Authors:  Leilei Tao; Guichun Huang; Rui Wang; Yan Pan; Zhenyue He; Xiaoyuan Chu; Haizhu Song; Longbang Chen
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

Review 3.  Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance.

Authors:  Shigeru Hashimoto; Ari Hashimoto; Ryuta Muromoto; Yuichi Kitai; Kenji Oritani; Tadashi Matsuda
Journal:  Cells       Date:  2022-08-22       Impact factor: 7.666

4.  LIM domain only 2 over-expression in prostate stromal cells facilitates prostate cancer progression through paracrine of Interleukin-11.

Authors:  Chen-Yi Jiang; Jun-Jie Yu; Yuan Ruan; Xiao-Hai Wang; Wei Zhao; Xing-Jie Wang; Yi-Ping Zhu; Yuan Gao; Kui-Yuan Hao; Lei Chen; Bang-Min Han; Shu-Jie Xia; Fu-Jun Zhao
Journal:  Oncotarget       Date:  2016-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.